dc.contributor
Institut Català de la Salut
dc.contributor
[González-Barcala FJ] Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain. Respiratory Medicine, Universidad de Santiago de Compostela, Santiago de Compostela, Spain. [Muñoz-Gall X] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER of Respiratory Diseases (CIBERes), Madrid, Spain. Departament de Biologia Cel•lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Mariscal E, García A] GlaxoSmithKline, Madrid, Spain. [Yang S] GlaxoSmithKline, Collegeville, PA, USA. [van de Wetering G] Pharmerit International, Rotterdam, the Netherlands. [Izquierdo-Alonso JL] Medicine and Specialities Department, Universidad de Alcalá (Alcalá de Henares, Madrid), Hospital Universitario Guadalajara, Guadalajara, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Mariscal, Esther
dc.contributor.author
García, Andrea
dc.contributor.author
Yangg, Shibing
dc.contributor.author
van de Wetering, Gijs
dc.contributor.author
Izquierdo Alonso, José Luis
dc.contributor.author
Gonzalez-Barcala, Francisco-Javier
dc.contributor.author
Muñoz, Xavier
dc.date.accessioned
2025-10-24T10:40:12Z
dc.date.available
2025-10-24T10:40:12Z
dc.date.issued
2022-06-09T08:21:22Z
dc.date.issued
2022-06-09T08:21:22Z
dc.identifier
González-Barcala FJ, Muñoz-Gall X, Mariscal E, García A, Yang S, van de Wetering G, et al. Cost-effectiveness analysis of Anti–IL-5 therapies of severe eosinophilic asthma in Spain. J Med Econ. 2021;24(1):874–882.
dc.identifier
https://hdl.handle.net/11351/7654
dc.identifier
10.1080/13696998.2021.1941065
dc.identifier
000673521500001
dc.identifier.uri
https://hdl.handle.net/11351/7654
dc.description.abstract
Asma eosinofílica greu; Comparació indirecta del tractament; Mepolizumab
dc.description.abstract
Severe eosinophilic asthma; Indirect treatment comparison; Mepolizumab
dc.description.abstract
Asma eosinofílica severa; Comparación de tratamiento indirecto; Mepolizumab
dc.description.abstract
Aim
To analyse the cost-effectiveness of MEP with standard of care (SoC) versus other anti-IL-5 therapies approved for the treatment of severe eosinophilic asthma (SEA) patients, within the Spanish National Health System (NHS) perspective.
Methods
A Markov model with a 4-week cycle length was used to compare MEP with BEN and RES as therapies added to SoC in the management of SEA, in terms of cost per QALY gained and incremental cost-effectiveness ratio (ICER). Costs (€2019) were obtained from public sources, while utilities and transition probabilities were retrieved from literature, e.g. network meta-analysis. Continuation criteria for biological treatment and reduction of oral corticosteroids (OCS) was set at 50% minimum reduction of exacerbation rate. Adverse events related to chronic OCS use included diabetes, osteoporosis, cataracts, acute myocardial infarct, and peptic ulcer. The analysis was performed over a 5-year time horizon from the National Healthcare System (NHCS) perspective, with a yearly discount rate of 3% applied to both costs and QALYs. Probabilistic sensitivity analysis and univariate deterministic sensitivity analysis were performed to address uncertainty around the cost-effectiveness results.
Results
On top of SoC, the model indicates that MEP is dominant (lower cost, higher benefit) compared to BEN and RES: For BEN and RES, respectively, treatment with MEP had a point estimate of 0.076 and 0.075 additional QALYs, and savings of €3,173.47 and €7,772.95 per patient. The findings were robust to variation as estimated using sensitivity analysis.
Conclusions
MEP is a cost-effective treatment in comparison with BEN and RES added to SoC for patients with SEA in the Spanish setting.
dc.description.abstract
This study was funded by GlaxoSmithKline [Study code: HO-19-19968].
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Taylor & Francis
dc.relation
Journal of Medical Economics;24(1)
dc.relation
https://doi.org/10.1080/13696998.2021.1941065
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Hormones esteroides - Ús terapèutic
dc.subject
CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
HEALTH CARE::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis
dc.subject
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Eosinophilia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas de la corteza suprarrenal
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::análisis coste-beneficio
dc.subject
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::eosinofilia
dc.title
Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
